



An Alzheimer's Disease Study

Aim

To investigate the efficacy of a 12-month treatment of RO4602522 versus placebo added to background therapy of acetylcholinesterase inhibitors donepezil or rivastigmine in patients with moderate severity Alzheimer's disease (AD)

Phase II

Multicenter, randomized, double-blind, parallel-group, placebo-controlled study (BP28248)

Hypothesis

The cause of AD is unknown and there are no curative treatments. Many therapeutic approaches are under investigation that target key proteins: amyloid A β and tau. Monoamine oxidase-B (MAO-B) activity is increased in the brain from the early stages of dementia. MAO-B activity increases the production of toxic reactive oxygen species (free radicals) that contribute to the pathogenesis of AD. This study explores the hypothesis that the novel MAO-B inhibitor RO4602522 might exert a therapeutic benefit in moderate AD.

Trial No. NCT01677754

Ethics approval

Lighthouse Institutional Review Centre
HREC (EC00433)

Funding

F Hoffmann-La Roche Ltd

Criteria

To be eligible for this study subjects must:

- be 50–90 years old,
- have a Mini-Mental State Examination (MMSE) score of 14–20,
- have a Body Mass Index (BMI) 18–36,
- have a carer for at least 10 hours per week.

Status

Now enrolling

Contact

Professor Peter K Panegyres
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
185 York Street, Subiaco WA 6008
Phone: (08) 6380 2255
Fax: (08) 6380 2055
Email: research@ndr.org.au